To increase or decrease dosage of antimicrobials in septic patients during continuous renal replacement therapy: The eternal doubt

Current Opinion in Pharmacology

Volumn 24, Issue , 2015, Pages 68-78

  Wong, Wai Tat ^a   Choi, Gordon ^a   Gomersall, Charles D ^a   Lipman, Jeffrey ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; DAPTOMYCIN; DORIPENEM; MEROPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ACUTE KIDNEY FAILURE; ARTICLE; CONTINUOUS RENAL REPLACEMENT THERAPY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG MONITORING; HUMAN; MAINTENANCE DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRESCRIPTION; PRIORITY JOURNAL; SEPSIS; KIDNEY FAILURE; METABOLISM; RENAL REPLACEMENT THERAPY;

ANTI-BACTERIAL AGENTS; COLISTIN; DAPTOMYCIN; DRUG MONITORING; HUMANS; RENAL INSUFFICIENCY; RENAL REPLACEMENT THERAPY; SEPSIS;

EID: 84948949147     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2015.07.003     Document Type: Review

References (42)

1. G. Choi, C.D. Gomersall, Q. Tian, G.M. Joynt, R. Freebairn, and J. Lipman Principles of antibacterial dosing in continuous renal replacement therapy Crit. Care Med. 37 2009 2268 2282
2. J. Lee, S. Han, S. Jeon, T. Hong, W. Song, H. Woo, and D.S. Yim Population pharmacokinetic analysis of colistin in burn patients Antimicrob. Agents Chemother. 57 2013 2141 2146
3. B. Preiswerk, A. Rudiger, J. Fehr, and N. Corti Experience with daptomycin daily dosing in ICU patients undergoing continuous renal replacement therapy Infection 41 2013 553 557
4. D. Khadzhynov, T. Slowinski, I. Lieker, C. Spies, B. Puhlmann, T. Konig, A. Uhrig, K. Eggers, H.H. Neumayer, F. Traunmuller, and et al. Plasma pharmacokinetics of daptomycin in critically ill patients with renal failure and undergoing CVVHD Int. J. Clin. Pharmacol. Ther. 49 2011 656 665
5. K.S. Akers, J.M. Cota, C.R. Frei, K.K. Chung, K. Mende, and C.K. Murray Once-daily amikacin dosing in burn patients treated with continuous venovenous hemofiltration Antimicrob. Agents Chemother. 55 2011 4639 4642
6. J.A. Roberts, M.H. Abdul-Aziz, J. Lipman, J.W. Mouton, A.A. Vinks, T.W. Felton, W.W. Hope, A. Farkas, M.N. Neely, J.J. Schentag, and et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions Lancet Infect. Dis. 14 2014 498 509
7. S.R. Bauer, C. Salem, M.J. Connor Jr., J. Groszek, M.E. Taylor, P. Wei, A.J. Tolwani, and W.H. Fissell Pharmacokinetics and pharmacodynamics of piperacillin-tazobactam in 42 patients treated with concomitant CRRT Clin. J. Am. Soc. Nephrol. 7 2012 452 457
8. B. Harvey, T.N. Johnson, D. Yeomanson, H. Mulla, and A.P. Mayer Ceftriaxone pharmacokinetic properties during continuous veno-veno haemofiltration using an in vitro adult, paediatric and neonatal model Perfusion 29 2014 32 38
9. M. Ulldemolins, S. Vaquer, M. Llaurado-Serra, C. Pontes, G. Calvo, D. Soy, and I. Martin-Loeches Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy Crit. Care 18 2014 227
10. D.M. Roberts, J.A. Roberts, M.S. Roberts, X. Liu, P. Nair, L. Cole, J. Lipman, and R. Bellomo Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study Crit. Care Med. 40 2012 1523 1528
11. M. Beumier, G.S. Casu, M. Hites, L. Seyler, F. Cotton, J.L. Vincent, F. Jacobs, and F.S. Taccone Beta-lactam antibiotic concentrations during continuous renal replacement therapy Crit. Care 18 2014 R105
12. J.A. Jamal, B.A. Mueller, G.Y. Choi, J. Lipman, and J.A. Roberts How can we ensure effective antibiotic dosing in critically ill patients receiving different types of renal replacement therapy? Diagn. Microbiol. Infect. Dis. 2015
13. J.A. Roberts, and D.M. Roberts Antibiotic dosing in critically ill patients with septic shock and on continuous renal replacement therapy: can we resolve this problem with pharmacokinetic studies and dosing guidelines? Crit. Care 18 2014 156
14. S.L. Goldstein, and T.D. Nolin Lack of drug dosing guidelines for critically ill patients receiving continuous renal replacement therapy Clin. Pharmacol. Ther. 96 2014 159 161
15. L. Awdishu, and J. Bouchard How to optimize drug delivery in renal replacement therapy Semin. Dial. 24 2011 176 182
16. T. Yamamoto, N. Yasuno, S. Katada, A. Hisaka, N. Hanafusa, E. Noiri, N. Yahagi, T. Fujita, and H. Suzuki Proposal of a pharmacokinetically optimized dosage regimen of antibiotics in patients receiving continuous hemodiafiltration Antimicrob. Agents Chemother. 55 2011 5804 5812
17. B. Moriyama, S.A. Henning, M.M. Neuhauser, R.L. Danner, and T.J. Walsh Continuous-infusion beta-lactam antibiotics during continuous venovenous hemofiltration for the treatment of resistant Gram-negative bacteria Ann. Pharmacother. 43 2009 1324 1337
18. L. Seyler, F. Cotton, F.S. Taccone, D. De Backer, P. Macours, J.L. Vincent, and F. Jacobs Recommended beta-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy Crit. Care 15 2011 R137
19. Y. Ohchi, S. Hidaka, K. Goto, R. Shitomi, T. Nishida, T. Abe, S. Yamamoto, N. Yasuda, S. Hagiwara, and T. Noguchi Effect of hemopurification rate on doripenem pharmacokinetics in critically ill patients receiving high-flow continuous hemodiafiltration Yakugaku Zasshi 131 2011 1395 1399
20. C. Covajes, S. Scolletta, L. Penaccini, E. Ocampos-Martinez, A. Abdelhadii, M. Beumier, F. Jacobs, D. de Backer, J.L. Vincent, and F.S. Taccone Continuous infusion of vancomycin in septic patients receiving continuous renal replacement therapy Int. J. Antimicrob. Agents 41 2013 261 266
21. J.A. Jamal, A.A. Udy, J. Lipman, and J.A. Roberts The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens Crit. Care Med. 42 2014 1640 1650
22. A.A. Udy, C. Covajes, F.S. Taccone, F. Jacobs, J.L. Vincent, J. Lipman, and J.A. Roberts Can population pharmacokinetic modelling guide vancomycin dosing during continuous renal replacement therapy in critically ill patients? Int. J. Antimicrob. Agents 41 2013 564 568
23. C.B. Landersdorfer, and R.L. Nation Colistin: how should it be dosed for the critically ill? Semin. Respir. Crit. Care Med. 36 2015 126 135
24. M. Karvanen, D. Plachouras, L.E. Friberg, E. Paramythiotou, E. Papadomichelakis, I. Karaiskos, I. Tsangaris, A. Armaganidis, O. Cars, and H. Giamarellou Colistin methanesulfonate and colistin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration Antimicrob. Agents Chemother. 57 2013 668 671
25. N. Markou, M. Fousteri, S.L. Markantonis, B. Zidianakis, D. Hroni, E. Boutzouka, and G. Baltopoulos Colistin pharmacokinetics in intensive care unit patients on continuous venovenous haemodiafiltration: an observational study J. Antimicrob. Chemother. 67 2012 2459 2462
26. M. Leporati, R.O. Bua, F. Mariano, P. Carignano, M. Stella, L. Biancone, and M. Vincenti Determination by LC-MS/MS of colistins A and B in plasma and ultrafiltrate from critically ill patients undergoing continuous venovenous hemodiafiltration Ther. Drug Monit. 36 2014 182 191
27. P.M. Honore, R. Jacobs, J. De Regt, V. Van Gorp, E. De Waele, and H.D. Spapen Colistin dosing for treatment of multidrug-resistant Pseudomonas in critically ill patients - please, be adequate! Crit. Care 18 2014 412
28. N. Corti, A. Rudiger, A. Chiesa, I. Marti, A. Jetter, K. Rentsch, D. Muller, M. Bechir, and M. Maggiorini Pharmacokinetics of daily daptomycin in critically ill patients undergoing continuous renal replacement therapy Chemotherapy 59 2013 143 151
29. M. Falcone, A. Russo, M.I. Cassetta, A. Lappa, L. Tritapepe, S. Fallani, V. Vullo, M. Venditti, and A. Novelli Daptomycin serum levels in critical patients undergoing continuous renal replacement J. Chemother. 24 2012 253 256
30. A.M. Vilay, M. Grio, D.D. Depestel, K.M. Sowinski, L. Gao, M. Heung, N.N. Salama, and B.A. Mueller Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis Crit. Care Med. 39 2011 19 25
31. J.M. Wenisch, B. Meyer, V. Fuhrmann, K. Saria, C. Zuba, P. Dittrich, and F. Thalhammer Multiple-dose pharmacokinetics of daptomycin during continuous venovenous haemodiafiltration J. Antimicrob. Chemother. 67 2012 977 983
32. S.M. Bhavnani, C.M. Rubino, P.G. Ambrose, and G.L. Drusano Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis Clin. Infect. Dis. 50 2010 1568 1574
33. M. Benvenuto, D.P. Benziger, S. Yankelev, and G. Vigliani Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers Antimicrob. Agents Chemother. 50 2006 3245 3249
34. G. Wong, A. Brinkman, R.J. Benefield, M. Carlier, J.J. De Waele, N. El Helali, O. Frey, S. Harbarth, A. Huttner, B. McWhinney, and et al. An international, multicentre survey of beta-lactam antibiotic therapeutic drug monitoring practice in intensive care units J. Antimicrob. Chemother. 69 2014 1416 1423
35. J.A. Roberts, M. Ulldemolins, M.S. Roberts, B. McWhinney, J. Ungerer, D.L. Paterson, and J. Lipman Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept Int. J. Antimicrob. Agents 36 2010 332 339
36. D.M. Roberts, X. Liu, J.A. Roberts, P. Nair, L. Cole, M.S. Roberts, J. Lipman, and R. Bellomo A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics Crit. Care 19 2015 84
37. J.M. Varghese, P. Jarrett, S.C. Wallis, R.J. Boots, C.M. Kirkpatrick, J. Lipman, and J.A. Roberts Are interstitial fluid concentrations of meropenem equivalent to plasma concentrations in critically ill patients receiving continuous renal replacement therapy? J. Antimicrob. Chemother. 70 2015 528 533
38. E.N. Frazee, P.J. Kuper, G.E. Schramm, S.L. Larson, K.B. Kashani, D.R. Osmon, and N. Leung Effect of continuous venovenous hemofiltration dose on achievement of adequate vancomycin trough concentrations Antimicrob. Agents Chemother. 56 2012 6181 6185
39. W. Chaijamorn, A. Jitsurong, K. Wiwattanawongsa, U. Wanakamanee, and P. Dandecha Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients Int. J. Antimicrob Agents 38 2011 152 156
40. D.M. D'Arcy, E. Casey, C.M. Gowing, M.B. Donnelly, and O.I. Corrigan An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration BMC Pharmacol. Toxicol. 13 2012 14
41. F.S. Taccone, D. de Backer, P.F. Laterre, H. Spapen, T. Dugernier, I. Delattre, P. Wallemacq, J.L. Vincent, and F. Jacobs Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy Int. J. Antimicrob. Agents 37 2011 531 535
42. A.M. Spooner, C. Deegan, D.M. D'Arcy, C.M. Gowing, M.B. Donnelly, and O.I. Corrigan An evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous veno-venous haemodiafiltration BMC Clin. Pharmacol. 11 2011 11